Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes Compass platform, which allows to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 28, 2019 and is headquartered in San Francisco, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
125
Frequently Asked Questions
What is Market Cap of Maze Therapeutics Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Maze Therapeutics Inc. market cap is $702.49M.
What is the 52-week high for Maze Therapeutics Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Maze Therapeutics Inc. 52 week high is $19.19 as of September 12, 2025.
What is the 52-week low for Maze Therapeutics Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Maze Therapeutics Inc. 52 week low is $6.71 as of September 12, 2025.
What is Maze Therapeutics Inc. stock price today?
Maze Therapeutics Inc. stock price today is $24.80.
What was Maze Therapeutics Inc. stock price yesterday?
Maze Therapeutics Inc. stock price yesterday was $16.02.
What is the PE ratio of Maze Therapeutics Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Maze Therapeutics Inc.’s P/E ratio is -9.51.
What is the Price-to-Book ratio of Maze Therapeutics Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Maze Therapeutics Inc. P/B ratio is 2.6788.
What is the 50-day moving average of Maze Therapeutics Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Maze Therapeutics Inc. 50-day moving average is $14.73.
How many employess does Maze Therapeutics Inc. has?
